Inti Labs

What Inti Labs does

Inti Labs is a fertility technology company founded in 2022 and headquartered in Baytown, United States, with an operational footprint extending to Taiwan (intilabs.tw). The company builds molecular diagnostic products for IVF and reproductive medicine, serving fertility clinics, reproductive endocrinologists, and fertility specialists globally. Its product portfolio is structured around the IVF journey and includes OPAL (an egg quality test co-developed with Dr. Barry Behr of Stanford University), Pixl (a next-generation PGT-A platform using SNP-based targeted sequencing, or stNGS), ora® (a non-invasive endometrial receptivity test analyzing microRNA expression via the proprietary PanelChip® platform), and ora® Reserve (a sample storage add-on enabling future-cycle testing).

The company's underlying technology centers on proprietary molecular diagnostics, including microRNA expression profiling from endometrial tissue and blood samples, and SNP-based targeted sequencing for embryo chromosomal analysis. Published validation includes a March 2024 MDPI study demonstrating 93.9% accuracy, 85.3% sensitivity, and 92.4% specificity for ora® in identifying the optimal embryo transfer window, and a December 2023 MDPI study showing 95.9% accuracy for the blood-based microRNA prediction model. An April 2021 Fertility and Sterility publication reported >90% accuracy for the PanelChip in predicting displaced window of implantation in repeated implantation failure patients.

Inti Labs generates revenue through the sale of fertility diagnostic kits and laboratory testing services to fertility clinics and healthcare professionals. Its go-to-market is enterprise field sales with direct partnerships and distributor relationships worldwide. The company also supports demand generation through content marketing (IVF Guide, blog, clinical evidence pages) and a clinic finder tool that directs patients to partner clinics. Research and validation partnerships with Lee Women's Hospital and Chung Shan Medical University (Taiwan) anchor the scientific credibility of the platform.

Name

Inti Labs

Legal name

Inti Labs

Website

https://intilabs.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Inti Labs is a fertility technology company that develops molecular diagnostic products, including egg quality testing, preimplantation genetic screening, and microRNA-based endometrial receptivity analysis, for fertility clinics and reproductive medicine specialists worldwide.

Ownership category

akta.pro rank

Product category

Fertility Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic & Prenatal Testing Laboratories (HLAFAMAH)

Keywords

• Fertility diagnostics
• IVF testing products
• Preimplantation genetic screening
• Endometrial receptivity testing
• MicroRNA diagnostic platform

Headquarters

HQ city

Baytown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Fertility Diagnostic Products: Inti Labs generates revenue through the sale of fertility diagnostic products and services to fertility clinics and healthcare professionals, including OPAL egg quality test, Pixl PGT-A testing, and ora® endometrial receptivity testing solutions.
2. Laboratory Testing Services: The company provides laboratory testing services through its proprietary technology platform, analyzing patient samples (endometrial tissue, blood, embryos) and delivering personalized results to fertility clinics.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Inti Labs develops and sells fertility diagnostic products for use in IVF, including OPAL (egg quality test), Pixl (next-generation PGT-A platform), and ora® (non-invasive endometrial receptivity test using proprietary microRNA PanelChip technology). The company provides laboratory testing services by analyzing patient samples and delivering personalized results to fertility clinics and reproductive health specialists.

Product overview

Inti Labs is a fertility technology company offering a comprehensive portfolio of diagnostic products designed to enhance IVF success rates and provide personalized solutions. The portfolio includes OPAL (egg quality test), Pixl (next-generation PGT-A genetic screening), ora® (non-invasive endometrial receptivity test), and ora® Reserve (sample storage service). These products work together to address different stages of the IVF journey: OPAL for identifying egg quality, Pixl for embryo selection through chromosomal screening, ora® for personalized embryo transfer timing, and ora® Reserve for future cycle preparedness.

Differentiator

Problem solved

Functional benefit

Brands

• Opal: Egg quality test developed alongside Dr. Barry Behr of Stanford University, designed to evaluate egg quality and obtain vital insights for fertilization and freezing.
• Pixl
• ora®
• ora® Reserve

Products and services

• OPAL OPAL is an egg quality test that evaluates egg quality and provides vital insights for fertilization and freezing. Developed alongside Dr. Barry Behr of Stanford University, OPAL helps fertility specialists identify egg quality to support IVF decision-making.
• Pixl PGT-A Pixl is a Next Generation PGT-A (Preimplantation Genetic Testing for Aneuploidy) platform that uses SNP-based targeted sequencing (stNGS) to identify chromosomal abnormalities often missed by traditional low-coverage whole-genome amplification methods. It detects aneuploidy, mosaicism, abnormal ploidy, uniparental disomy (UPD), and microdeletions/microduplications to support embryo selection during IVF.
• ora® Non-Invasive Endometrial Receptivity Test ora® is the first and only non-invasive endometrial receptivity test that analyzes endometrial gene expression to identify a patient's unique implantation window, helping improve the chances of successful embryo transfer without requiring mock cycles. Reported 93.9% accuracy, 85.3% sensitivity, and 92.4% specificity in identifying optimal embryo transfer timing.
• ora® Reserve ora® Reserve is a future-ready sample storage service that allows patients to prepare for multiple IVF cycles by storing genetic material for future ora® testing if implantation failure occurs, enabling rapid determination through ora® testing if a displaced window of implantation contributed to implantation failure.

Quantifiable outcome

• 93.9% accuracy in identifying optimal timing for embryo transfer
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• Lee Women's HospitalcoreStrategic or Co-development PartnerResearch partnership with Lee Women's Hospital and Chung Shan Medical University resulting in a recent study and publication demonstrating promising findings for ora® Non-Invasive Endometrial Receptivity Test. The study yielded positive results regarding the test's effectiveness in determining endometrial receptivity.
• Chung Shan Medical UniversitycoreStrategic or Co-development PartnerCollaborated with Lee Women's Hospital on research study published in March 2024, focusing on the ora® Non-Invasive Endometrial Receptivity Test. Contributed to the scientific validation of the company's endometrial receptivity testing technology.
• Dr. Barry Behr (Stanford University)coreStrategic or Co-development PartnerCo-developed the OPAL egg quality test alongside Dr. Barry Behr of Stanford University. Dr. Behr is a renowned expert in reproductive medicine and embryology, bringing scientific credibility and expertise to the product development.

Recent moves6 records

Expansion highlights5 records

Direct peers

• Igenomix (Vitrolife): Igenomix, now part of Vitrolife, is the established leader in endometrial receptivity testing (ERA) and preimplantation genetic testing (PGT). It competes head-to-head with Inti Labs' ora® and Pixl products across the same fertility clinic customer base.
• CooperSurgical (CooperGenomics): CooperGenomics, the reproductive genetics arm of CooperSurgical, offers PGT-A and related IVF genetic services to clinics. It is one of the most entrenched incumbents in the PGT space and directly competes with Inti Labs' Pixl platform.
• Genea Biomedx: Genea Biomedx develops IVF lab instruments, media, and analytics used by fertility clinics. It overlaps with Inti Labs in providing tools that improve embryo handling and IVF lab workflow outcomes for the same clinic customers.

Broad incumbents

• Natera: Natera is a large molecular diagnostics company whose reproductive health portfolio (including Empower, Spectrum PGT-A) targets the same IVF clinics as Inti Labs. It is a broader incumbent with deeper sales reach and recurring embryo testing volume.
• FUJIFILM Irvine Scientific: FUJIFILM Irvine Scientific provides IVF media, culture systems, and lab supplies to fertility clinics globally. As a broad IVF incumbent, it competes for the same clinic wallet share as Inti Labs across the broader IVF workflow.
• Invitae: Invitae is a large genetic testing company with reproductive health offerings (PGT, carrier screening) serving fertility clinics. As a broader incumbent, it overlaps with Inti Labs' Pixl and general IVF genetic testing workflow.
• Quest Diagnostics: Quest Diagnostics is a major clinical laboratory network that processes reproductive and genetic testing for clinics and patients. It overlaps with Inti Labs in clinical lab services for the fertility segment but at much broader scale.

Others

• Hamilton Thorne: Hamilton Thorne supplies specialty instruments and consumables for the IVF and cell therapy markets. While not a direct molecular diagnostic competitor, it serves the same fertility clinic channel and adjacent IVF lab workflow.

Emerging players

• Celmatix: Celmatix is a precision medicine company focused on fertility and reproductive health, developing diagnostics and analytics for IVF. It overlaps with Inti Labs on biomarker-driven fertility testing targeting reproductive endocrinologists.
• BillionToOne: BillionToOne is a precision diagnostics company whose UNITY prenatal test and oncology assays demonstrate a molecular diagnostics platform model similar to Inti Labs' microRNA-based approach, addressing reproductive health screening with novel chemistry.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inti Labs